Stock PPGN POLYPEPTIDE GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Company PolyPeptide Group AG

Equities

PPGN

CH1110760852

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 05:29:21 2024-06-05 am EDT 		5-day change 1st Jan Change
32.02 CHF -0.70% Intraday chart for PolyPeptide Group AG +1.42% +82.93%
May. 13 Donaldson Company, Inc. and PolyPeptide Group AG Partners to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology CI
Mar. 12 PolyPeptide Group AG Provides Earnings Guidance for 2024 CI

Business Summary

Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.

Number of employees: 1,273

Sales per Business

CHF in Million2022Weight2023Weight Delta
Custom Projects
48.2 %
141 49.8 % 150 48.2 % +6.75%
Contract Manufacturing
42.3 %
111 39.4 % 132 42.3 % +18.32%
Generics and Cosmetics
9.5 %
30 10.7 % 30 9.5 % -2.08%

Sales per region

CHF in Million2022Weight2023Weight Delta
Europe and Asia
71.0 %
192 67.9 % 221 71.0 % +15.45%
United States
29.0 %
90 32.1 % 90 29.0 % -0.41%

Managers

Managers TitleAgeSince
Juan-José Gonzalez CEO
 Chief Executive Officer 52 23-04-11
Olivier Ludemann-Hombourger CTO
 Chief Tech/Sci/R&D Officer 52 11-12-31
Jens Fricke COO
 Chief Operating Officer 59 22-11-30
Jane Anne Salik BRD
 Director/Board Member 71 05-12-31
Michael Stäheli IRC
 Investor Relations Contact 59 21-03-31
Jon Holbech Rasmussen LAW
 General Counsel 54 98-12-31
Monika Casanova HRO
 Human Resources Officer 45 22-05-08
Neil James Thompson SAM
 Sales & Marketing 52 03-12-31
Christina Del Vecchio LAW
 General Counsel 46 21-08-31

Members of the board

Members of the board TitleAgeSince
Patrick Aebischer BRD
 Director/Board Member 70 20-12-31
Peter Wilden CHM
 Chairman 67 21-03-31
Jane Anne Salik BRD
 Director/Board Member 71 05-12-31
Beat In-Albon BRD
 Director/Board Member 72 20-12-31
Philippe Weber BRD
 Director/Board Member 59 20-12-31
Erik Schropp BRD
 Director/Board Member 60 20-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,125,001 12,958,584 ( 39.12 %) 155,494 ( 0.4694 %) 39.12 %

Shareholders

NameEquities%Valuation
Frederik Paulsen
56.10 %
18,582,406 56.10 % 614 M CHF
Rudolf Maag
3.321 %
1,100,000 3.321 % 36 M CHF
PRIMECAP Management Co.
3.203 %
1,061,016 3.203 % 35 M CHF
Newtyn Management LLC
3.009 %
996,794 3.009 % 33 M CHF
T. Rowe Price International Ltd.
2.990 %
990,437 2.990 % 33 M CHF
HBM Partners AG (Investment Management)
0.9660 %
320,000 0.9660 % 11 M CHF
Joh. Berenberg, Gossler & Co. KG (Investment Management)
0.3582 %
118,652 0.3582 % 4 M CHF
Lupus alpha Asset Management AG
0.1660 %
55,000 0.1660 % 2 M CHF
Seven Canyons Advisors LLC
0.1098 %
36,385 0.1098 % 1 M CHF
Swiss Fund Management AG
0.0906 %
30,000 0.0906 % 991 114 CHF

Company contact information

PolyPeptide Group AG

Neuhofstrasse 24

6340, Baar

+41 435 020 580

http://www.polypeptide.com
address PolyPeptide Group AG(PPGN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for PolyPeptide Group AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
33.31 EUR
Average target price
25.12 EUR
Spread / Average Target
-24.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
POLYPEPTIDE GROUP AG Stock PolyPeptide Group AG
+82.93% 1.2B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.83% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.70% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.06% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.63% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.75% 246B
NOVARTIS AG Stock Novartis AG
+11.02% 213B
ROCHE HOLDING AG Stock Roche Holding AG
-3.11% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.43% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PPGN Stock
  4. Company PolyPeptide Group AG